52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
J&J Prepares To Resume Phase 3 Ensemble Trial Of Janssen Covid-19 Vaccine Candidate In U.S.
Genmab Announces IFM, Hovon And Janssen Achieve Positive Topline Results In Second Part Of Phase 3 Cassiopeia Study Of Daratumumab In Multiple Myeloma At Pre-Planned Interim Analysis
Janssen Receives Positive CHMP Opinion For Long-Acting Regimen For The Treatment Of Hiv
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Biotechnology & Drugs
1 Johnson And Johnson Plz
NEW BRUNSWICK, NJ
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.
Oct 23 - Johnson & Johnson said on Friday it was preparing to resume a large clinical trial of its experimental COVID-19 vaccine in the United States after an independent safety panel recommended enrollments for the study.
Johnson & Johnson's coronavirus vaccine trial will resume very soon after investigators concluded a participant's illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter. (Reporting by Munsif Vengattil; Editing...
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters.
GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.
GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.
Asian equities slipped on Wednesday as halted COVID-19 vaccine trials and an impasse in U.S. fiscal aid package talks soured risk appetite, while the greenback held on to gains as demand firmed for safe-harbour assets.
Asian equities were set to slip on Wednesday as halted COVID-19 vaccine trials and an elusive U.S. stimulus agreement weighed on investor sentiment, while the dollar rose from Tuesday's three-week low as demand firmed for safe-haven assets.
The U.S. dollar rose from a three-week low on Tuesday while shares in Europe and the United States eased, as news of a pause in Johnson & Johnson's COVID-19 vaccine trial led investors to take stock of recent rallies before chasing further gains.
Johnson & Johnson said on Tuesday it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing its total payment to $5 billion.
* J&J, AstraZeneca vaccines both based on adenoviruses (Adds comment from former FDA head, background, share move)
Latin American currencies and stocks fell on Tuesday as global risk sentiment took a hit from Johnson & Johnson's move to pause its COVID-19 vaccine trials and on a worsening emerging market growth outlook from the International Monetary Fund. Markets were spooked by U.S...
The S&P 500 and the Dow opened lower as a pause in Johnson & Johnson's COVID-19 vaccine trials weighed, while the Nasdaq rose ahead of major events scheduled for Apple and Amazon.com.
Johnson & Johnson raised its annual profit forecast for the second time this year in quarterly results on Tuesday, a day after it was the second major drug company to call a temporary halt to trials of its experimental coronavirus vaccine.
Johnson & Johnson reported a 1.7% rise in third-quarter sales on Tuesday due to higher demand for its cancer drugs, a day after the company said it had paused its COVID-19 vaccine trials.
Johnson & Johnson's COVID-19 vaccine study has been paused due to an unexplained illness in a study participant, Stat News reported on Monday, citing a document obtained by the news organization.
(Adds AstraZeneca's Canada and Thailand deals, RDIF deals with Uzbekistan, Egypt, India, Nepal and Brazil; Updates Johnson & Johnson's EU agreement) Oct 12 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies...
The European Union has sealed a deal with Johnson & Johnson to supply up to 400 million doses of its potential COVID-19 vaccine, as the bloc builds up stocks amid a global scramble to secure shots.
Johnson & Johnson will pay more than $100 million to settle over 1,000 lawsuits that allege the company's Baby Powder caused cancer, Bloomberg news reported on Monday https://www.bloomberg.com/news/articles/2020-10-05/j-j-to-pay-more-than-100-million-to-end-over-1-000-talc-suits...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.